Lung Cancer

Pralsetinib has been approved in Hong Kong, China, for use in treatment-naïve and pretreated adult patients with RET fusion–positive, metastatic non–small cell lung cancer.

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.

Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.

A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.

Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.

Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.

Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.

Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.

The panel discusses how the field of small cell lung cancer treatment has changed in recent years.